Ractigen Therapeutics Kicks Off Multi-Center Phase II Clinical Trial of First-in-Class saRNA Therapeutic RAG-01 for Non-Muscle Invasive Bladder Cancer

A Phase II study has begun at Fudan University Shanghai Cancer Center under the leadership of Principal Investigator Professor Ding-Wei Ye, bringing together 11 urologic oncology centers across China. The study includes a safety run-in phase followed by multiple cohorts; the available article text provides no treatment details or clinical results.